Lynx Dx Launches Ordering for At-Home Collection Version of MyProstateScore 2.0

Convenient test now available for ordering by physicians, eligible for Medicare reimbursement.

ANN ARBOR, Mich., Feb. 20, 2025 /PRNewswire/ -- Lynx Dx, a leader in innovative diagnostic solutions, today announced the commercial launch of MyProstateScore 2.0 (MPS2) for at-home collection by patients. The test kit, ordered by a physician, is now available to patients and is eligible for Medicare reimbursement.

The launch follows research published in the Journal of Urology that found MPS2 delivers market-leading accuracy in predicting the risk of clinically significant prostate cancer even without conducting a digital rectal exam (DRE) before collecting a urine sample.

"Giving patients the option to take the test at home, without the need to schedule a visit to the doctor or have a DRE, adds convenience, removes stigma and broadens access to a powerful method of screening for a serious disease," said Spencer Heaton, Chief Medical Officer at Lynx Dx. "MyProstateScore 2.0 offers more clarity about the need for a biopsy in a way that aligns seamlessly with modern clinical workflows."

The study in Journal of Urology, found that MPS2 significantly outperformed traditional prostate-specific antigen (PSA) testing by identifying up to 53% of men whose biopsy would be negative while maintaining 91–94% sensitivity for high-grade cancer (Grade Group ≥2). While PSA testing remains the gold standard of prostate cancer screening, the test provides an incomplete picture and results in overutilization of prostate biopsies, three-quarters of which come back negative for clinically significant prostate cancer.

Physicians can now order MPS2 for patients to complete without a DRE, either in the office or at home. This flexibility makes MPS2 compatible with telehealth practices and enhances access for patients in underserved areas. The collected urine samples remain stable without temperature control or special packaging, ensuring reliable results and the ability to ship samples any day of the week.

"The accuracy and convenience of the MPS2 biomarker test, available for at-home or in-office use, has enabled me to confidently consider deferring initial or repeat prostate biopsies in men with elevated PSA levels," said Jeffrey Bassett, MD, MPH, a board-certified urologist with Hoag in Newport Beach, Calif.

Physicians can order MPS2 test kits for delivery by contacting Lynx Dx's Client Services team at 1-888-978-8677 or [email protected].

About MyProstateScore 2.0 (MPS2)

MPS2 is a urine test designed to predict the presence of clinically significant prostate cancer by analyzing expression of 18 unique gene transcripts, including the T2:ERG gene fusion, the most specific biomarker for prostate cancer. The test optimizes diagnostic accuracy for both biopsy naïve patients and those with a prior negative biopsy. Additionally, it provides diagnostic flexibility with optional assessment of personalized risk factors known to influence the development of clinically significant prostate cancer.

About Lynx Dx

Using technology developed at the University of Michigan, Lynx Dx provides best-in-class diagnostic testing services to help people live healthy and productive lives. The company's mission is to develop superior genomic tests where there is clear patient need. Lynx Dx produces tests with the highest degree of accuracy and efficiency combined with unparalleled customer experience. For more information about Lynx Dx and MyProstateScore 2.0, please visit www.lynxdx.com.

Media contact
Chad Van Alstin
[email protected]
941-281-5821

SOURCE Lynx Dx